SCHEMBL30983413

SCHEMBL30983413

CC(=O)N1CCN(CCOc2cc(C)c(-c3nc4c(OC5(C)CC5)ncnc4n3Cc3ccccc3)cn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 4/20 0.42
▸ PIK3CD O00329 5/20 0.40
▸ GALR3 O60755 1/20 0.36
▸ NR2F2 P24468 1/20 0.36
▸ ALK Q9UM73 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR1D P28221 1/20 0.35
▸ HTR1B P28222 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CNR1 P21554 2/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ GRM4 Q14833 1/20 0.34
▸ RET P07949 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983475 0.96 SIGMAR1 (0.40) SIGMAR1PIK3CDGALR3NR2F2HTR1A
SCHEMBL30983537 0.91 PIK3CD (0.40) SIGMAR1PIK3CDHTR1AHTR1DHTR1B
SCHEMBL30983871 0.90 PIK3CD (0.41) SIGMAR1PIK3CDHTR1AHTR1DHTR1B
SCHEMBL30983453 0.88 PIK3CD (0.39) PIK3CDHTR1AHTR1DHTR1B
SCHEMBL30983552 0.87 PIK3CD (0.40) PIK3CDHTR1A
SCHEMBL30983498 0.86 MAOB (0.40) SIGMAR1PIK3CDALKKDM4EALDH1A1
SCHEMBL30983437 0.86 PIK3CD (0.40) PIK3CDGALR3NR2F2CNR1CNR2
SCHEMBL30983452 0.86 HTR1D (0.40) SIGMAR1PIK3CDHTR1AHTR1DHTR1B
SCHEMBL30983872 0.85 PIK3CD (0.39) PIK3CDHTR1AHTR1DHTR1B
SCHEMBL30983804 0.85 TLR7 (0.39) SIGMAR1PIK3CDHTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB SIGMAR1 1702/4885PIK3CD 434/4885GALR3 2347/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB SIGMAR1 1702/4885PIK3CD 434/4885GALR3 2347/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB SIGMAR1 1702/4885PIK3CD 434/4885GALR3 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback